SCHEDULE: Fuller & Thaler Amends Integra LifeSciences Stake

Fuller & Thaler Asset Management, Inc. has updated its beneficial ownership in Integra LifeSciences Holdings Corp., reporting a 4.67% stake as of December 31, 2025.

Summary

• Fuller & Thaler Asset Management, Inc. filed an Amendment No. 1 to its Schedule 13G for Integra LifeSciences Holdings Corp.
• As of December 31, 2025, Fuller & Thaler beneficially owned 3,636,359.96 shares of Integra LifeSciences' Common Stock.
• This ownership represents 4.67% of the class of securities.
• Fuller & Thaler Asset Management, Inc. holds sole voting power over 3,583,652.96 shares and sole dispositive power over 3,636,359.96 shares.
• The filing confirms that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. Schedule 13G amendments are standard regulatory disclosures and typically do not convey significant positive or negative sentiment regarding the issuer's operational or financial performance.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures by institutional investors, indicating their passive ownership stakes in public companies. This amendment reflects an updated position by Fuller & Thaler Asset Management in Integra LifeSciences, a common occurrence as fund managers adjust their portfolios.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which is now below the 5% threshold.

Key Dates

Keywords

Integra LifeSciences Holdings Corp, Fuller & Thaler Asset Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Asset Management